TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05554380

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study: NCT06015880

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Description: Given IV
Study: NCT04726592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Description: Ketoprofen 100 mg IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metoclopramide
Description: Metoclopramide 10 mg IV
Study: NCT06015880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT06305767

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Administered via intravenous (IV) infusion at a dose of 400 mg on Day 1 of every 6-week cycle for up to 9 adjuvant cycles for Adjuvant Cohort participants, or at a dose of 200 mg on Day 1 of every cycle for up to four 3-week neoadjuvant cycles and up to thirteen 3-week adjuvant cycles for Perioperative Cohort participants.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered via intravenous (IV) infusion at a dose of 400 mg on Day 1 of every 6-week cycle for up to 9 adjuvant cycles for Adjuvant Cohort participants, or at a dose of 200 mg on Day 1 of every cycle for up to four 3-week neoadjuvant cycles and up to thirteen 3-week adjuvant cycles for Perioperative Cohort participants.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered via intravenous (IV) infusion at a dose of 400 mg on Day 1 of every 6-week cycle for up to 9 adjuvant cycles for Adjuvant Cohort participants, or at a dose of 200 mg on Day 1 of every cycle for up to four 3-week neoadjuvant cycles and up to thirteen 3-week adjuvant cycles for Perioperative Cohort participants.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V940
Description: Administered via intramuscular (IM) injection at a dose of 1 mg every 3 weeks for a total of up to 9 adjuvant doses for Adjuvant Cohort participants, or at a dose of 1 mg every 3 weeks for a total of up to 9 doses in the neoadjuvant and adjuvant periods for Perioperative Cohort participants.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V940
Description: Administered via intramuscular (IM) injection at a dose of 1 mg every 3 weeks for a total of up to 9 adjuvant doses for Adjuvant Cohort participants, or at a dose of 1 mg every 3 weeks for a total of up to 9 doses in the neoadjuvant and adjuvant periods for Perioperative Cohort participants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: V940 diluent only (saline and/or dextrose) administered via IM injection Q3W for up to 9 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: Administered via IV infusion at a dose of 1.25 mg/kg on Day 1 and Day 8 of every cycle for up to four 3-week neoadjuvant cycles and up to five 3-week adjuvant cycles for Perioperative Cohort participants.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery (RC plus PLND)
Description: Curative intent surgery (RC plus PLND) will be administered to all participants in the Perioperative Cohort and will be done in accordance with the American Urological Association/American Society for Radiation Oncology/American Society of Clinical Oncology/Society of Urologic Oncology guidelines. RC plus PLND will be performed within 6 weeks of the last dose of neoadjuvant V940 plus pembrolizumab plus EV treatment. Adjuvant V940 plus pembrolizumab plus EV treatment will begin within 8 weeks of completing RC plus PLND.
Study: NCT06425159

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BHV-7000
Description: BHV-7000 75mg. Participants will take blinded investigational product (IP) once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo taken once daily
Study: NCT06429527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WHOeyes combined with a questionnaire.
Description: The WHOeyes app (a self-administered visual acuity testing app) plus a questionnaire (to ask the patients to go to the hospital if they ever experience ocular discomfort including eye redness, discharge, etc.) will be used for 1-week follow-up after cataract surgery, and only those with significant vision loss based on WHOeye test or with ocular discomfort are advised to return to the hospital for follow-up.
Study: NCT05438459

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Phase I part
Description: Administration of GAIA-102 as a monotherapy or GAIA-102 and pembrolizumab in combination.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Phase I part
Description: Administration of GAIA-102 as a monotherapy or GAIA-102 and pembrolizumab in combination.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Phase II part
Description: Randomized into group of administration of GAIA-102 as a monotherapy or GAIA-102 or pembrolizumab in combination, group of standard treatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Phase II part
Description: Randomized into group of administration of GAIA-102 as a monotherapy or GAIA-102 or pembrolizumab in combination, group of standard treatment
Study: NCT05141266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: PN involves 8 weekly telephonic sessions lasting 30-45 minutes (telephonic to support lower-costs/sustainability). In session 1, the navigator reviews with the participant a report of scores from the baseline assessment to understand the participant's current health needs/challenges; session 1 also involves development of therapeutic alliance/rapport and goal setting. Sessions 2-4 focus on goal setting and identifying barriers and problem resolutions. The navigator elicits motivation and discusses this in context of readiness to change heath behavior and self-management skills. Sessions 2-4 also involve navigators supporting/assisting patients to fill out paperwork and enroll in needed social services and/or mental/behavioral/physical healthcare, including but not limited to primary care. Sessions 5-7 focus on encouraging and reinforcing treatment adherence, review-ing and identifying other care needs, and offering linkages to service providers as applicable

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Medication Counseling (SMC)
Description: SMC participants receive a single medication information/counseling session delivered by a University of Utah pharmacist to: (1) offer counseling, (2) document counseling was offered, (3) offer a counseling process for patients not present (not applicable to this study given all patients must screen in person), and (4) discuss generic substitution.
Study: NCT05551728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ESDM-informed caregiver coaching
Description: The coaching intervention is informed by the Community-Early Start Denver Model (C-ESDM). The intervention has been adapted for the South African context. Training procedures have been adapted for delivery by non-specialist coaches. Twelve session-specific visuals with simple-text (for caregivers) and session scripts (for non-specialist coaches) have been developed. Over 12, 1-hour caregiver coaching sessions that are delivered by non-specialists, caregivers are coached in strategies to increase child attention to their social world, increase child communication, create and build joint activity routines, and understand and use the ABCs to support the development of new behaviors.
Study: NCT05916560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered SC.
Study: NCT04726592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: Metoclopramide 10 mg IV
Study: NCT06660537

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balloon-blowing exercises in 90/90 bridge position with a ball.
Description: In this group patients will undergo balloon-blowing exercises in the 90/90 bridge position with a ball. In this intervention, patients lie on back with feet against a wall and knee bent at 90 degrees, holding a ball between their knees. While extending one arm overhead and holding a balloon in the other hand, perform a pelvic tilt without lifting their back off the mat. Inhale through the nose, exhale into the balloon for four breaths, then remove the balloon and repeat the sequence four times. The 4-week protocol includes three supervised sessions per week, each supervised by a physiotherapist. Progress will be monitored regularly to evaluate improvements throughout the intervention.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Buteyko breathing exercises management
Description: In this group, patients will receive Buteyko breathing exercises, which consist of two main exercises; the control pause and the maximum pause. For control pause, patients exhale, plug the nose, and hold their breath until they feel the urge to breathe, then inhale and breathe normally for 10 seconds. In Maximum pause, patients exhale, plug their nose, and hold their breath as long as possible, aiming for double the control pause time, then inhale and breath normally for 10 seconds. This is a 4-week protocol with three sessions per week. Pre- and post-intervention values will be recorded to assess progress.
Study: NCT06606548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: comprehensive oral care
Description: including cleaning, facial massage, oral muscle massage and stretching, and oral moisturizing.
Study: NCT06607653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Olfactory training
Description: Olfactory training used repeated stimulation of different olfactory substances at high concentrations, combined with odor association and odor identification training, twice in the morning and evening, each time for 5 minutes, for 15 weeks.
Study: NCT06608082

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: indocyanine green injected intravenously
Description: During the procedure, after performing the hysterectomy, indocyanine green will be injected intravenously into the patient. A fluorescence video of the vaginal cuff will be recorded. The fluorescence of the recorded images will be analyzed by fluorescence analysis software to obtain an objective value of fluorescence.
Study: NCT06608524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-regulated learning strategy
Description: The experimental group uses self-regulated strategy.This program selects classroom performance , homework quality , experimental operation, and test score as academic performance (score) evaluation variables.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard learming method
Description: The control group uses standard learming method. The program selects classroom performance, homework quality, experimental operation, and test score evaluation form as academic performance (score) evaluation variables.
Study: NCT05300568

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-product related survey.
Study: NCT05947565

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Invasive Urodynamic Study
Description: Invasive Urodynamic Study (Filling cystometry and pressure-flow study) Under sterile conditions and at lithotomy position, an urethral and a rectal catheter will be inserted. Bladder will be filled by sterile saline slowly. The first feeling of urine, the first sensation of urination and the sensation of severe desire to urinate will be recorded step by step. Vesical, rectal and detrusor pressures will be monitorized during these period. After the strong desire to void sensation, filling cystometry phase will be completed. Sterile saline infusion is stopped.~While the patient urinates the vesical, detrusor and rectal pressures, the maximum and average urine flow rates will be recorded.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Invasive Urodynamic Study
Description: Invasive Urodynamic Study (Filling cystometry and pressure-flow study) Under sterile conditions and at lithotomy position, an urethral and a rectal catheter will be inserted. Bladder will be filled by sterile saline slowly. The first feeling of urine, the first sensation of urination and the sensation of severe desire to urinate will be recorded step by step. Vesical, rectal and detrusor pressures will be monitorized during these period. After the strong desire to void sensation, filling cystometry phase will be completed. Sterile saline infusion is stopped.~While the patient urinates the vesical, detrusor and rectal pressures, the maximum and average urine flow rates will be recorded.
Study: NCT05514756

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active t-VNS
Description: Active t-VNS at 8 Hz for up to 60 minutes will be applied to the left cymba conchae

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham t-VNS
Description: Sham t-VNS at 8 Hz for up to 60 minutes will be applied to the left earlobe

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Baseline assessments
Description: Baselines assessments with no stimulation will serve as control in this three-part crossover design
Study: NCT04710550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F18-3F4AP
Description: PET Scan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F18-3F4AP
Description: PET Scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F18-3F4AP
Description: PET Scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F18-3F4AP
Description: PET Scan
Study: NCT05610618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual stimulation
Description: Participants will be displayed with photographs of scenes and objects which predictability and sharpness will be manipulated
Study: NCT06036017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Earplugs
Description: There are numerous studies that suggest using earplugs can regulate a patient's sleep and may reduce the risk of delirium (Locihova 2017) (Van Rompaey 2012). However, there is no hard and fast rule concerning the duration, timing, and preference of earplug use. The duration of earplug use may vary and will be determined based on the needs of the patient, and it will be ensured that they are used throughout the night (Rompaey 2012).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Music therapy will be applied to help the patient relax and fall asleep. Moreover, the choice of music genre will be suitable for the patient's preferences, and it will be ensured that it is played at a low volume. Specific guidelines will be applied regarding the frequency and duration of music therapy, it will be performed twice a day after surgery at a low volume and via headphones, each session lasting 30 minutes (Sibenda A et al. 2019).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Presence of Family After Extubation:
Description: According to the guidelines titled 'Family presence and visit in Adult ICU' published by the American Association of Critical Care Nurses (AACN) in 2012; it is recommended that a family member or friend chosen by the patient be present to provide 24-hour uninterrupted emotional and social support for patients in intensive care. Allowing the patient's family to visit helps maintain the patient's social connections and contributes to the psychological well-being of the patient with family support. In addition to routine visits, patients' families can spend longer periods with the patient during their intensive care process and information about the patient is conveyed to close family members. Research shows that family presence in the intensive care unit reduces the incidence of delirium (Eghbali-Babadi, 2017) (Rosa 2017).
Study: NCT05474638

Intervention type: DEVICE
Group type: OTHER
Intervention: Isometric Thumb Force (isometric mechanomyography) compared to TOF-Watch SX (acceleromyography)
Description: Comparison of mechanomyographic measurements of thumb adduction's force induced by 100 versus 200 Hz 5 seconds tetanic ulnar nerve stimulation during neuromuscular block spontaneous recovery monitored by acceleromyography on the controlateral arm.
Study: NCT04077346

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biostim-5 transcutaneous spinal stimulator
Description: Transcutaneous spinal stimulation (TcStim): The 5-channel stimulator capable of generating (41) pain-free biphasic rectangular waveform of 0.3- to 1.0-ms pulses with a frequency of 5-10 kHz will be used to stimulate at single or multi-site spinal levels.~TcStim will be delivered in combination with activity based locomotor training in 5 - 10 minute of stimulation at sub-motor threshold daily (5x/week) for 60 sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Spinal Stimulator + Activity Based Locomotor Training
Description: Participants will receive a combination of Activity-based locomotor training (AB-LT)+TcStim daily (5x/week) for 60 sessions and will consist of a minimum of 55-60 min on the TM for facilitated standing/stepping followed by 30 min of activities off TM in sitting, standing, or stepping.
Study: NCT04603443

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Branched Chain Amino Acids
Description: Isoleucine, Leucine, and Valine, 10g BID x 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Branched Chain Amino Acids
Description: Isoleucine, Leucine, and Valine, 20g BID x 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Branched Chain Amino Acids
Description: Isoleucine, Leucine, and Valine, 30g BID x 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Protein Control
Description: Protein placebo control - all amino acids except for BCAA, 10g BID x 12 weeks
Study: NCT05817110

Intervention type: OTHER
Intervention: Participant Cohort
Description: Patients coming to the facility for chest x-rays for any reason, will undergo x-rays as ordered by their treating clinician. In case of any nodule detection by qXR, it will be classified either as low-risk (Lung nodule malignancy score ) LNMS or high-risk LNMS confirmed by radiologist. Then if patient is eligible will be included in the study and a CT Scan will be requested upon enrolment of the patient.
Study: NCT04636528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital rehabilitation
Description: Patients in the digital intervention group will benefit from an 8-week program composed of therapeutic exercise, education and cognitive behavioural therapy (CBT) program provided by SWORD Health.~Patients in this group will performed home-based rehabilitation sessions using SWORD Phoenix®, under remote monitoring by a physical therapist.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Patients in this group will benefit from a 8-week program consisting of two 30 min face-to-face physical therapy sessions per week in an outpatient clinic setting, for a total of 16 sessions. The program includes commonly used interventions adapted by the physical therapist to the specific needs of the participant.~In addition to the face-to-face sessions, physical therapists will also be communicating with participants in this group through a secure messaging system (Mychart) used at UCSF or, alternatively, through a telephone check-ins (10-15 min calls, up to twice per week).
Study: NCT05064813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction MBSR Intervention
Description: MBSR is an 8-week group-based course developed by Jon Kabat-Zinn (1990) and colleagues at the University of Massachusetts' Center for Mindfulness. Weekly 2.5 hour long classes are given once a week, as well as one day-long weekend class. The classes instruct participants in the theory and practice of several forms of mindfulness meditation, breathing awareness, and mindfulness stretching exercises. Teaching of the theory of mindfulness and experiential practice are both utilized during weekly classes and at-home CD-guided practice sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Education Control Condition (SE)
Description: Stress Education (SE) was designed to provide an active comparator condition that does not include overlapping active components of mindfulness meditation with MBSR. It will also be delivered over 8-weekly, in-person, 2.5 hour group sessions of the same size (n=4 to 6). In SE, participants receive extensive information about stress and health, but will not receive any MBSR or other mind-body training. Instead, stress relevant psycho-educational information will be taught.
Study: NCT05917119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BLT
Description: Bright light therapy delivered via glasses

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: s-BLT
Description: sham delivered with bright light therapy glasses to which a neutral density filter has been applied
Study: NCT05918575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation alternating with high flow nasal cannula
Description: A total of 24 hours of prophylactic respiratory support will be provided using NIV alternating with HFNC with total NIV usage of 16 hours and HFNC usage of 8 hours.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal cannula
Description: A total of 24 hours of prophylactic respiratory support will be provided using HFNC alone.
Study: NCT05988866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lipodia
Description: Participants will receive access to the digital health intervention lipodia in addition to TAU.
Study: NCT06413654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B001
Description: The subjects will receive IV dose of B001 on Day 1 and Day 15 of RCP

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects will receive IV dose of placebo matched to B001 on Day 1 and Day 15 of the RCP